Daratumumab plus anti-CD20 rescues refractory recurrent FSGS after transplant
This real-world cohort suggests combined plasma-cell and B-cell depletion can induce remission and free apheresis-dependent patients with recurrent FSGS who have exhausted standard therapy.
📅 Journal publication: Sep 2026(online Jun 16, 2026)·Last updated: Aug 9, 2026
Can dual antibody therapy offer a lifeline for transplant patients with recurrent FSGS?
Recurrent focal segmental glomerulosclerosis (rFSGS) after kidney transplantation is difficult to treat, and effective therapies are needed. In a study of 17 patients, 41% achieved complete remission and 24% achieved partial remission with combined anti-CD38 and anti-CD20 therapy. The combination therapy showed promising remission rates and reduced proteinuria in rFSGS, highlighting potential for wider clinical use pending further trials. Combined anti-CD38 and anti-CD20 therapy may offer new hope for managing refractory rFSGS post-kidney transplant.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Leon J, Ducrocq E, Lafargue MC, Bertrand D, Maigret L, Zaidan M, Colin AM, Thervet E, Durrbach A, Kamar N, Schvartz B, Bouvier N, Mazloum M, Bennani HN, Guezennec M, Es-Saleh D, Troger A, Burger C, Le Stang MB, Roger C, Hullekes F, Aubert O, Zuber J, Riella LV, Audard V, Anglicheau D
Citation:Leon J, Ducrocq E, Lafargue MC, et al. Anti-CD38/Anti-CD20 Rescue Therapy for Posttransplant Recurrent FSGS. Kidney international reports. 2026;11(9):106668. doi:10.1016/j.ekir.2026.106668